Ticagrelor Tablet
Product Images NDC 51407-861

Product Visual Gallery

This gallery contains 20 technical images submitted to the FDA as part of the official labeling for Ticagrelor (NDC 51407-861). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Golden State Medical Supply, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

51407-861-60lb (Ticagrelor 90 mg)

This text provides information about Ticagrelor Tablets with NDC 51407-861-60. Each film-coated tablet contains 90 mg of Ticagrelor. It is recommended to dispense the Medication Guide to each patient. The usual adult dosage and storage instructions are provided, and the tablets should be kept out of the reach of children at the recommended temperature range. The tablets are marketed by GSMS, Incorporated.*

FDA Label Image

Figure1.jpg (Figure1)

This is a comparison of two medications, Tigomg and Clopidogrel, in patients with events. The data includes the number of patients with events, the Kaplan-Meier survival percentages at 12 months, and the number of patients at risk at various time points. At 12 months, 362 out of 9235 patients (3.9%) experienced events while 306 out of 9186 (3.3%) with Clopidogrel. The Kaplan-Meier survival percentages were 45% for Tigomg and 38% for Clopidogrel. The number of patients at risk decreased over time for both medications.*

FDA Label Image

Figure10.jpg (Figure10)

This document contains information related to a study comparing the outcomes of two treatments, TioOmg and Clopidogrel, in patients with events. The data includes the number of patients with events, Kaplan-Meier percentages at 12 months, hazard ratio, confidence interval, p-value, and the number of days from randomization. The study suggests that TioOmg has a lower event rate compared to Clopidogrel based on the hazard ratio and p-value provided.*

FDA Label Image

Figure11.jpg (Figure11)

This text provides detailed information on the characteristics of a study or trial, including demographics, treatment approaches, patient history, and treatment outcomes such as the Overall Treatment Effect, Geographic distribution, ASA dose levels, planned treatment approach, and more. The data includes percentages and counts for various subgroups, as well as efficacy results for different medications (Ticagrelor and Clopidogrel) broken down by age groups, sex, and other factors. Additionally, it shows confidence intervals and treatment effect estimates based on the outcomes observed.*

FDA Label Image

Figure12.jpg (Figure12)

This data table provides information on the efficacy of Ticagrelor and Clopidogrel in different regions classified as US versus Non-US. The table shows the number of cases for each drug at different dose levels categorized by regions and responses. Measures of efficacy, such as Hazard Ratios (HR) with a 95% confidence interval (Ci), are also included in the table. The outcomes suggest that Ticagrelor may be better than Clopidogrel in terms of effectiveness based on the provided data.*

FDA Label Image

Figure13.jpg (Figure13)

The text provides information on a clinical trial comparing the effects of Ti90mg, Ti60mg, and Placebo over a period of 36 months. It includes data on the number of patients with events, Kaplan-Meier percentages, hazard ratios, and p-values. The text also shows the number of patients at risk over days from randomization for each group. This data can be used to analyze the efficacy of different treatments in the study.*

FDA Label Image

Figure14.jpg (Figure14)

The information provided appears to be statistical data showing various characteristics and demographic information regarding a medical study. It includes details such as treatment effects, patient demographics, medical history, and efficacy of Ticagrelor compared to placebo. The data seems to be organized in rows and columns, presenting HR (Hazard Ratio) values along with confidence intervals. This data can be used to evaluate the effectiveness and safety of Ticagrelor in the specified study population.*

FDA Label Image

Figure15.jpg (Figure15)

FDA Label Image

Figure16.jpg (Figure16)

This data presents a detailed breakdown of patient characteristics such as age, sex, race, body mass index, geographic region, aspirin dose, HbA1c levels, eGFR, insulin use, history of angina, coronary artery disease, PCI history, time since PCI, history of CABG, time since CABG, smoking status, and duration of diabetes. Additionally, it provides information on the comparison between the drug Ticagrelor and placebo in terms of patient outcomes, with statistics like hazard ratios and confidence intervals. This information can be useful for researchers and healthcare professionals studying cardiovascular diseases and treatments.*

FDA Label Image

Figure17.jpg (Figure17)

This text provides information on the study comparing Ticagrelor 90 mg to a placebo in terms of events, cumulative percentage, and number of days from randomization. Ticagrelor had 303 events out of 5523 patients (5.4%), while the placebo had 362 events out of 5493 patients (6.5%). The table also shows the number of patients at risk over time from randomization.*

FDA Label Image

Figure18.jpg (Figure18)

The text presents a detailed analysis of a clinical trial comparing the efficacy of Ticagrelor versus Placebo in different subgroups of patients. It includes data on various factors such as age, sex, race, weight, geographic region, diagnosis, timing of events, comorbidities like diabetes mellitus, hypertension, prior stroke/TIA, heart disease, ASA and statin treatment, and smoking status. The results are displayed using Hazard Ratios (HR) and Confidence Intervals (CI) for each comparison. The study indicates that Ticagrelor shows better outcomes compared to Placebo in some subgroups while not in others.*

FDA Label Image

Figure2.jpg (Figure2)

FDA Label Image

Figure3.jpg (Figure3)

This information presents the cumulative percentage of events for two groups over different months from randomization. One group received Ticagrelor with 206 events out of 9562 participants, while the other group received Placebo with 100 events out of 9531 participants. The table also shows the number of participants at risk for each group at different time points.*

FDA Label Image

Figure4.jpg (Figure4)

This is a clinical trial data showing the results for Ticagrelor 90 mg bd (twice a day) versus Placebo. The number of events for Ticagrelor was 28 out of 5523 participants (0.5%), while for Placebo it was 7 out of 5493 participants (0.1%). The graph displays the cumulative incidence of events over time, with the number of participants at risk decreasing as time progresses. The data suggests that Ticagrelor may be associated with a higher incidence of events compared to Placebo.*

FDA Label Image

Figure5.jpg (Figure5)

FDA Label Image

Figure6.jpg (Figure6)

FDA Label Image

Figure7.jpg (Figure7)

This text provides information on the effect and dose adjustment recommendations of the medication Ticagrelor AR-CID4010XX based on intrinsic factors such as age, gender, ethnicity, renal impairment, end-stage renal disease, and hepatic impairment. It highlights the lack of dose adjustment needed for various conditions within these categories. The text discusses specific age ranges, gender considerations, ethnicities, and different levels of renal and hepatic impairment. It also mentions the administration of Ticagrelor as a single dose on a specific day.*

FDA Label Image

Figure8.jpg (Figure8)

This text provides recommendations and dosage guidelines for interacting drugs with Ticagrelor. It categorizes the drugs into strong, moderate, or potent CYP3A4 inhibitors, inducers, P-gP, and CYP3A inhibitors. Each drug has specific instructions listed including dose adjustments, avoidance of concomitant use, and reference change relative to Ticagrelor. It also mentions the mean effect and 90% confidence level of the drug AR-C124910XX.*

FDA Label Image

Figure9.jpg (Figure9)

FDA Label Image

Structure.jpg (Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.